Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

f 2008 and if the results of this trial are positive, Cadence submitting a new drug application (NDA) for Omigard in the first half of 2009; data from the celgosivir Phase II extension protocol being available by the end of 2007; 4-week interim results from the Phase II viral kinetics combination study of celgosivir in approximately 10 treatment-naive patients in October 2007; submitting an IND in the US in the first quarter of 2008 for the future development of celgosivir; Cutanea Life Sciences completing the Phase II CLS001 rosacea clinical trial in 2007; our estimate of the probable royalties payable to the holders of the convertible royalty participation units; the Company continuing to advance its highest priority programs while operating within an annual burn rate of $11 million to $13 million; and the Company's financial resources being sufficient to fund operations into the third quarter of calendar 2008.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: Cadence's ability to enroll sufficient patients to complete the Omigard CLIRS trial; the adequacy of the CLIRS trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including an NDA, for Omigard; our ability to manage licensing opportunities; our ability to initiate, fund and complete non-clinical studies, clinical studies, manufacturing and all ancillary activities within our expected timelines; our partner Cutanea Life Sciences completing a Phase II CLS001 rosacea clinical trial in 2007; to and future expense levels being within our current expectations.

Actual results or events could differ materially from the plans, intentions and expectations expressed or implied in any forward-looking statements, including the underlying assumptions thereto, as a result of numerous risks, uncertainties and other factors including: dependence on c
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms ... the activities in the soil or in the rhizosphere. ... stress on reducing environmental pollution and on reducing the ... segments the bio fertilizers market with analysis and forecasting ...
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to ... independent consultants, Protocol Networks has recently announced its expansion ... years, his company has attracted several clients in The ... well as others. With the success of these engagements, ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
... May 26 CEL-SCI Corporation (NYSE AMEX: ... developing an immune-based treatment for the "swine flu and ... Epitope Antigen Presentation System) vaccine technology. The Company ... gained from developing protective and therapeutic vaccines utilizing L.E.A.P.S. ...
... to participate in TED communityNEW YORK, May 26 ... new TED Fellows who will participate in TED,s annual ... join the TED community by attending TEDGlobal 2009, to ... TEDGlobal Fellows join the 40 TED Fellows selected for ...
... 26 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... ), a leading,fully integrated pharmaceutical company in the People,s ... production approval from,the State Food and Drug Administration (SFDA) ... Acyclovir gel is used to ...
Cached Biology Technology:CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 2CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 3CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 4TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford 2TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford 3TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford 4TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford 5China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs 2China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs 3
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... of California, Riverside have made a discovery in the ... drugs and explore novel strategies for treating seizures associated ... Americans. Neurons, the basic building blocks of the ... and chemical signaling. During epileptic seizures, which generally ...
... Mike Jaffe,s recent book chapter about sugar-based chemicals ... series, must-read list. "Sugar-Based Chemicals for Environmentally ... Symposium Series http://pubs.acs.org/doi/abs/10.1021/bk-2010-1061.ch001 and is racking ... doctoral student and research professors A. J. East ...
... This month in ecological science, researchers evaluate the U.S. National ... in the return of a native lizard to the Ozarks ... us about the Arctic Tundra,s fire regime. These articles ... Ecological Society of America,s (ESA) journals. Taking ...
Cached Biology News:UC Riverside neuroscientists' discovery could bring relief to epilepsy sufferers 2Sugar-based chemicals book chapter by NJIT professor takes ACS kudos 2US National Fire Plan, return of Ozark lizard and the Arctic Tundra's fire regime 2US National Fire Plan, return of Ozark lizard and the Arctic Tundra's fire regime 3
... Acetate: CoA ligase (AMP forming), Acetate thiokinase ... protein content. Physical form: Lyophilized ... and reduced glutathione Preparation Unit ... of S-acetyl coenzyme A from acetate, ATP ...
SCCRO (S-17)...
...
... is a nucleoside antibiotic ... is a potent translational ... and eukaryotic cells. Resistance ... by the products of ...
Biology Products: